Thumbnail Image
Publication

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

Ferolla, P
; 
Brizzi, M
; 
Meyer, T
; 
Mansoor, Was
; 
Mazieres, J
; 
Do Cao, C
; 
Léna, H
; 
Berruti, A
; 
Damiano, V
; 
Buikhuisen, W
... show 10 more
Citations
Altmetric:
Abstract
There are no data from prospective studies focused exclusively on patients with advanced lung and thymic carcinoids. We aimed to assess the efficacy and safety of long-acting pasireotide and everolimus, administered alone or in combination, in patients with advanced carcinoids of the lung or thymus.
Authors
Ferolla, P
Brizzi, M
Meyer, T
Mansoor, Was
Mazieres, J
Do Cao, C
Léna, H
Berruti, A
Damiano, V
Buikhuisen, W
Grønbæk, H
Lombard-Bohas, C
Grohé, C
Minotti, V
Tiseo, M
De Castro, J
Reed, N
Gislimberti, G
Singh, N
Stankovic, M
Öberg, K
Baudin, E
Affiliation
Department of Medical Oncology, Multidisciplinary NET Group, Umbria Regional Cancer Network and University of Perugia, Perugia, Italy.
Description
Date
2017-10-23
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. 2017, Lancet Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/620677
Embedded videos